impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Review

 

Systemic lupus erythematosus: one year in review 2026

1, 2, 3, 4, 5, 6, 7, 8, 9, 10

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa; and GenOMeC PhD Program, University of Siena, Italy.
  2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. dinazucchi@hotmail.it
  3. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa; and GenOMeC PhD Program, University of Siena, Italy.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  5. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  6. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Itlay.
  7. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
  8. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  9. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
  10. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

CER19809
2026 Vol.44, N°3
PI 0427, PF 0437
Review

Free to view
(click on article PDF icon to read the article)

Received: 15/02/2026
Accepted : 06/03/2026
In Press: 11/03/2026
Published: 11/03/2026

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by a complex pathogenesis, heterogeneous clinical manifestations and a variable disease course. This review summarises the most relevant contributions on SLE published during 2025, following the framework of the One Year in Review series. In particular, we focus on emerging pathogenetic insights, novel and refined biomarkers, clinical manifestations and outcomes, comorbidities, and evidence from clinical trials and real-world studies, highlighting both recent progress and persistent unmet needs in the management of SLE.

DOI: https://doi.org/10.55563/clinexprheumatol/mg0q41

Rheumatology Article